Amgen and Eli Lilly lead in immune disease treatments, with Amgen targeting GLP-1 market share from Lilly.

Amgen Inc. and Eli Lilly and Company are key players in the immune-mediated inflammatory diseases treatment market. Amgen aims to expand its presence by competing in the GLP-1 market, currently dominated by Eli Lilly. Both companies have strengths and weaknesses in their drug portfolios, making the competition significant for investors considering long-term prospects. This analysis explores which company might be a better investment based on their market positions and drug offerings.